Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
The Adeno-Associated Virus (AAV) is a non-enveloped, small single-stranded DNA Parvovirus that commonly infects humans but has no known pathology. Its genome contains two open reading frames, Rep and Cap, which are flanked by two inverted terminal repeats (ITR). In addition to Rep and Cap, AAV requires a helper plasmid containing the adenovirus genes E2a, E4, and VA. These genes mediate the AAV replication.
Creative Biogene's AAV products stand as the pinnacle for precise gene expression and modification across diverse cell and tissue types, boasting unparalleled efficiency and safety enhancements.
Highlights of Our Premade AAV Particles
Creative Biogene has developed the most comprehensive line of reporter AAV product for all your research applications.
Creative Biogene has a wide variety of AAV particles expressing recombinase Cre, Cas9, FLPo etc.
Creative Biogene is proud to offer a range of premade AAV control particles that come ready-to-use.
Creative Biogene is proud to offer a range of calcium or glutamate biosensor products that come ready-to-use.
Creative Biogene is proud to offer AAV viral vectors that can be used critical research tools to study the underlying mechanisms of Parkinson's disease.
Creative Biogene offers AAV particles contains different tissue-specific promoters driven gene expression in certain cell types.
Creative Biogene is proud to offer ready-to-use viral preparations in the PHP.B, PHP.eB, and PHP.S serotype.
Creative Biogene has On-shelf scAAV particles expressing gene including GFP, Cre recombinase etc.
Creative Biogene offers AAV particles carrying the DNA genome of Hepatoviruses, as a useful tool for establishing the chronic Hepatovirus infection mouse model.
Adeno-associated virus (AAV) demonstrate high biosafety via minimal viral elements, elicit low immunogenicity through compact genomes, efficiently transduce diverse cell types via broad host range and serotype options, and achieve sustained transgene expression and spread in nondividing cells like neurons. The recombinant AAV design strategically retains inverted terminal repeats for vector genome processing while removing other viral genes onto separate plasmids, enabling safe, customizable, and efficient gene delivery across various tissues.
You can utilize Creative Biogene's various AAV products to design experiments such as:
Case Study 1
Pantothenate Kinase-Associated Neurodegeneration (PKAN) is a hereditary disorder characterized by progressive motor coordination impairment, resulting from PANK2 gene mutations encoding a human pantothenate kinase isoform. Most PANK2 mutations diminish enzyme activity, impacting coenzyme A (CoA) synthesis critical for energy metabolism and lipid synthesis. CoA levels are tightly regulated by Nudt7 and Nudt19-mediated degradation. Researchers aimed to reduce neuronal CoA levels in mice by enhancing degradation through overexpressing a cytosolic soluble Nudt7 version (scAAV9-Syn-Nudt7cyt), resulting in significantly lowered brain CoA levels and impaired motor coordination.
Figure 1. GFP expression is driven by the CMV or Syn promoter. Injecting self-complementary AAV9 (scAAV9) with GFP expression under the CMV promoter (scAAV9-CMV-GFP) led to strong GFP expression in brown adipose tissue, muscle, brain, and spinal cord. (Shumar S A, et al., 2015)
Case Study 2
Piezo2 is a low-level neurotransmitter in the peripheral nervous system. Threshold mechanosensory receptors serve as transducers of touch and proprioception. The scientists analyzed balance and coordination deficits caused by the selective deletion of channels in proprioceptors (conditional knockout). Piezo2 was found to play a key role in a homogenous population of proprioceptive neurons that innervate head muscles, indicating that this ion channel is critical for proprioceptive mechanotransduction in mammals.
Figure 2. Suppression of MA in MTN neurons from adult C57BL/6J mice by silencing Piezo2. Silencing its expression in MTN neurons by infecting MTN neurons of wild-type C57B1/6J mice with AAV carrying shRNA against Piezo2 (AAV-Piezo2-sh-1). (Florez-Paz D, et al., 2016)
Q: What is adeno-associated virus (AAV)?
A: AAV is a small, non-enveloped single-stranded DNA virus that was first discovered in 1965 as a contaminant during adenovirus preparation.
Q: What are the differences between AAV and adenovirus?
A: Compared to adenovirus, AAV has the following distinctions:
(1) Particle size difference. AAV particles are smaller with a diameter of ~20 nm, while adenovirus particles are larger with a diameter of 90-100 nm.
(2) Genome structure difference. AAV genome consists of single-stranded DNA, while adenovirus genome is double-stranded DNA.
(3) Replication dependence difference. AAV cannot autonomously replicate and relies on adenovirus co-infection, thus classified as a defective virus. Adenovirus can complete the viral replication cycle independently within host cells.
(4) Immunogenicity difference. AAV infection of human cells elicits minimal immune responses, while adenovirus infection often causes respiratory illnesses and other immune reactions.
(5) Host cell specificity difference. AAV can infect a variety of dividing and non-dividing cells, whereas adenovirus only infects actively dividing cells.
Q: How to select AAV types based on application scenarios?
A: The major considerations for selecting AAV types based on applications are:
(1) Different AAV serotypes have varying infection tropisms toward specific tissues and cell types, such as AAV9 for gene delivery into neuronal cells.
(2) Transgene capacity differs between single-stranded and self-complementary AAV, with ~4.7 kb and ~2.4 kb respectively, based on transgene size.
(3) Some engineered AAV variants (e.g. PHP series) enable enhanced transduction efficiency in certain cell types.
Q: How to evaluate AAV transfection efficiency?
A: Common methods to assess AAV transduction efficiency:
(1) Use fluorescent reporter genes and detect signal intensity.
(2) Measure the transgene copy number in target cells by qPCR.
(3) Assess the expression level of foreign transgene protein by Western blot.
Q: How to determine the required viral dose or multiplicity of infection (MOI)?
A: (1) Refer to empirical values in published literature for the initial dose setting.
(2) Perform serial infection experiments in cultured cells starting from low MOI to determine optimal MOI.
(3) Test low to high virus doses in animal models to identify the optimal dose for safety and transduction efficiency.
| Cat.No. | Product Name | Price |
|---|---|---|
| AAB0001 | CAG-GCaMP3 AAV (Serotype 8) | Inquiry |
| AAB0002 | CAG-FLEX-NES-jRGECO1b AAV (Serotype 8) | Inquiry |
| AAB0003 | CAG-FLEX-NES-jRGECO1a AAV (Serotype 8) | Inquiry |
| AAB0004 | CAG-FLEX-NES-jRCaMP1b AAV (Serotype 8) | Inquiry |
| AAB0005 | CAG-FLEX-GCaMP6s AAV (Serotype 8) | Inquiry |
| AAB0006 | CAG-FLEX-NES-jRCaMP1a AAV (Serotype 8) | Inquiry |
| AAB0007 | CMV-iGluSnFR AAV (Serotype 8) | Inquiry |
| AAB0008 | CAG-FLEX-CaMPARI AAV (Serotype 8) | Inquiry |
| AAB0009 | CAG-FLEX-GCaMP6m AAV (Serotype 8) | Inquiry |
| AAB0010 | CAG-FLEX-GCaMP6f AAV (Serotype 8) | Inquiry |
| AAB0011 | Syn-FLEX-CaMPARI AAV (Serotype 9) | Inquiry |
| AAB0012 | Syn-CaMPARI AAV (Serotype 9) | Inquiry |
| AAB0013 | pRSET.GCaMP5G(7.35) AAV (Serotype 9) | Inquiry |
| AAB0014 | CMV-iGluSnFR AAV (Serotype 9) | Inquiry |
| AAB0015 | Syn-FLEX-jGCaMP7c AAV (Serotype 9) | Inquiry |
Copyright © Creative Biogene. All rights reserved.